[go: up one dir, main page]

PE20040267A1 - Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas - Google Patents

Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas

Info

Publication number
PE20040267A1
PE20040267A1 PE2003000283A PE2003000283A PE20040267A1 PE 20040267 A1 PE20040267 A1 PE 20040267A1 PE 2003000283 A PE2003000283 A PE 2003000283A PE 2003000283 A PE2003000283 A PE 2003000283A PE 20040267 A1 PE20040267 A1 PE 20040267A1
Authority
PE
Peru
Prior art keywords
alkyl
nr9c
nrarb
phenyl
compounds
Prior art date
Application number
PE2003000283A
Other languages
English (en)
Inventor
Michael Curtin
Yuhia Dai
Steven K Davidsen
Michael R Michaelides
Yan Guo
Zhiqin Ji
Robin R Frey
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/103,621 external-priority patent/US20030181468A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20040267A1 publication Critical patent/PE20040267A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE DERIVADOS DE TIOPIRIMIDINAS E ISOTIAZOLPIRIMIDINAS INHIBIDORAS DE QUINASAS DE FORMULA (I) DONDE X ES -N- Y -CR3-; Z1 ES -N- Y -CR4; Z2 ES -N- Y CR5; Z3 ES -N- Y CR6; Z4 ES -N- Y CR7-; R1 ES H Y NH2; R2 ES ALCOXI, CIANO, HIDROXI, NITRO,-NRaRb Y -LR8; R3 ES H, ALQUENILO, ALCOXIALQUILO, ALQUILO, ARILALQUILO, CARBOXIALQUILO, HALO, HALOALQUILO, HETEROARILALQUILO, (HETEROCICLIL)ALQUILO, HIDROXIALQUILO, (NRaRb)ALQUILO Y (NRaRb)C(O)ALQUILO; R4, R5, R6, Y R7 ES H, ALCOXI, ALQUILO, NRaRb, HALO Y HIDROXI; R8 ES ALCOXIALQUILO, ALQUILO, ARILO, CICLOALQUILO, HETEROALQUILO, ENTRE OTROS; L ES -O-, -(CH2)nC(O)(CH2)p-, C=C-, (CH2)nO-, -C(O)NR9-, -NR9C(O)-, -NR9-, -(CH2)nNR9C(O)NR10(CH2)p-, -NR9C(S)NR10-, NR9C(=NCN)O, ENTRE OTROS. DONDE R9 Y R10 ES H, ALQUILO; m, n y p SON 0-2, CON LA SALVEDAD DE QUE AL MENOS UN Z1, Z2, Z3 Y Z4 SEA DISTINTO DE N. SON COMPUESTOS PREFERIDOS: N-[4-(4-AMINOTIEN[2,3-d]PIRIMIDIN-5-IL)FENIL]-N'-[2-FLUORO-5-(TRIFLUOROMETIL)FENIL]UREA; N-[4-(4-AMINOTIEN[2,3-d]PIRIMIDIN-5-IL)FENIL]-N'-(3-METILFENIL)UREA.LOS COMPUESTOS TIENEN ACTIVIDAD INHIBITORIA DE LAS PTK ESPECIFICAS (PROTEINA TIROSINA KINASA) COMO KDR Y Tie-2.TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE OBTENCION. ESTOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DEL CANCER.
PE2003000283A 2002-03-21 2003-03-21 Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas PE20040267A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/103,621 US20030181468A1 (en) 2002-03-21 2002-03-21 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US10/378,481 US20030225273A1 (en) 2002-03-21 2003-03-03 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20040267A1 true PE20040267A1 (es) 2004-05-01

Family

ID=28456596

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000283A PE20040267A1 (es) 2002-03-21 2003-03-21 Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas

Country Status (11)

Country Link
US (1) US20030225273A1 (es)
EP (1) EP1487841B1 (es)
JP (1) JP4526822B2 (es)
AR (1) AR039111A1 (es)
AU (1) AU2003220437A1 (es)
CA (1) CA2479363C (es)
ES (1) ES2453190T3 (es)
MX (1) MXPA04009142A (es)
PE (1) PE20040267A1 (es)
TW (1) TW200403999A (es)
WO (1) WO2003080625A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560552B2 (en) * 2002-03-21 2009-07-14 Abbott Laboratories Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
AU2003256755A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
ATE402705T1 (de) * 2003-12-24 2008-08-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
US20080108608A1 (en) * 2003-12-24 2008-05-08 Astrazeneca Ab Pyrimidines With Tie2 (Tek) Activity
PL1732921T3 (pl) * 2004-04-08 2009-04-30 Wyeth Corp Pochodne tioamidu jako modulatory receptora progesteronowego
EP1863805A1 (en) * 2005-02-01 2007-12-12 AstraZeneca AB Pyrimidine compounds having tie2 (tek) inhibitory activity
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US8143393B2 (en) * 2005-12-02 2012-03-27 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CA2631664C (en) * 2005-12-08 2012-05-08 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2008018881A1 (en) * 2006-08-10 2008-02-14 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
CA2706075A1 (en) * 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
MX370814B (es) * 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CN104860885B (zh) * 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
CN107641123A (zh) * 2016-07-20 2018-01-30 南京亿华药业有限公司 一种依鲁替尼及其关键中间体的制备新方法
CA3182275A1 (en) * 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1188529A (en) * 1966-06-09 1970-04-15 Wellcome Found Pyramidine Derivatives
JPH0578362A (ja) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd 縮合複素環化合物，その製造法，用途及び中間体
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
TR199900048T2 (xx) * 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
CA2283961A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
PL340589A1 (en) * 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
BR9913888A (pt) * 1998-09-18 2002-01-08 Basf Ag Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
SK3812002A3 (en) * 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
DE60037455T2 (de) * 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
US7427623B2 (en) * 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof

Also Published As

Publication number Publication date
JP2005526804A (ja) 2005-09-08
TW200403999A (en) 2004-03-16
CA2479363C (en) 2011-03-22
JP4526822B2 (ja) 2010-08-18
MXPA04009142A (es) 2004-11-26
AR039111A1 (es) 2005-02-09
CA2479363A1 (en) 2003-10-02
US20030225273A1 (en) 2003-12-04
EP1487841B1 (en) 2014-01-15
WO2003080625A1 (en) 2003-10-02
AU2003220437A1 (en) 2003-10-08
EP1487841A1 (en) 2004-12-22
ES2453190T3 (es) 2014-04-04

Similar Documents

Publication Publication Date Title
PE20040267A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
PE20020257A1 (es) Derivados biciclicos sustituidos como inhibidores de la proteina tirosina cinasa
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
PE20020532A1 (es) Derivados de naftaleno como agonistas del receptor canabinoide
ES2059327T3 (es) Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos.
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
AR043087A1 (es) Compuestos de pirrolotriazinas, utiles como inhibidores de cinasas y las composiciones farmaceuticas que los contienen
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AR031248A1 (es) Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
UY28150A1 (es) Agentes terapeuticos
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PE20081662A1 (es) DERIVADOS DE 6-OXO-6,7-DIHIDRO-5H-DIBENZO[b,d]AZEPIN-7-ILO

Legal Events

Date Code Title Description
FA Abandonment or withdrawal